An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects

Trial Profile

An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs Elenbecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 31 Mar 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 11 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Feb 2014, as per ClinicalTrials.gov record.
    • 22 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top